Olanzapine as an add-on, preoperative antiemetic drug in high-risk patients for postoperative nausea and vomiting: a double-blind, randomized trial

Published: 13 September 2021| Version 1 | DOI: 10.17632/5f2syxkzzf.1
Contributor:
THIAGO GRIGIO

Description

We conducted a randomized clinical trial in patients with cancer at high risk on postoperative nausea and vomiting (PONV) with a history of previous chemotherapy-induced nausea and vomiting who received total intravenous anaesthesia, to determine whether olanzapine, as a prophylactic antiemetic added to intraoperative dexamethasone and ondansetron, reduces the incidence of PONV in the first 24 hours or between 24 and 48 hours after surgery. The secondary outcomes were the incidence of severe PONV, the length of stay at the postanaesthesia care unit, antiemetic use as needed, and side effects. The file has two tabs. One tab for the analysis by intention to treat and another for the data dictionary

Files